Abstract Number: 1541 • ACR Convergence 2023
Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA
Background/Purpose: The aim of this study was to analyze the incidence of nervous system manifestations in a cohort of patients with Microscopic Polyangiitis (MPA) and…Abstract Number: 067 • 2023 Pediatric Rheumatology Symposium
Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis
Background/Purpose: The discovery of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis heralded a new class of neuropsychiatric illnesses mediated by autoantibodies, known collectively as autoimmune encephalitis. The clinical…Abstract Number: 0437 • ACR Convergence 2022
Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Background/Purpose: Neurologic involvement (NI) in ANCA-associated vasculitis (AAV) is common, occurring in approximately one-third of patients, and leads to significant and often chronic functional limitations…Abstract Number: 1475 • ACR Convergence 2022
Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus
Background/Purpose: Vascular events, including cerebrovascular accidents (CVA) occur earlier and more frequently in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies…Abstract Number: 1479 • ACR Convergence 2022
Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample
Background/Purpose: Neuromyelitis Optica (NMO), also known as Devic's disease, is a rare inflammatory demyelinating disorder causing myelitis and optic neuritis. While there have been reports…Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…Abstract Number: 1558 • ACR Convergence 2022
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…Abstract Number: 1844 • ACR Convergence 2022
Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital
Background/Purpose: Neurosarcoidosis (NS) is a severe complication of sarcoidosis. NS may be classified according to several subtypes. Data on therapy, including biological therapy (BT) is…Abstract Number: 1114 • ACR Convergence 2021
Pachymeningitis: The Mayo Clinic Experience
Background/Purpose: Pachymeningitis is a rare disorder defined by localized or generalized inflammatory thickening of the dura. It can be associated with infections, malignancy, autoimmune disorders,…Abstract Number: 1883 • ACR Convergence 2021
Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis. Neurological involvement, also known as Neuro-Behçet's disease (NBD), leads to great morbimortality. Diagnosis is challenging, since clinical…Abstract Number: 1885 • ACR Convergence 2021
Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Background/Purpose: Neurobehçet’s disease (NBD) is a severe complication of Behcet's disease (BD). Despite well-established therapies, with glucocorticoids and conventional immunosuppressants (cIS) a significant proportion of…Abstract Number: 0123 • ACR Convergence 2021
Vestibulocortical Stimulation with Caloric Irrigation Reduces Pain and Improves Subjective Well-Being in Fibromyalgia: An Open-Label Pilot Trial
Background/Purpose: Safe and effective therapies for fibromyalgia (FM) remain a major unmet clinical need. Vestibulocortical stimulation (VCS) via caloric irrigation is a safe, inexpensive, non-invasive…Abstract Number: 0417 • ACR Convergence 2021
Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Background/Purpose: The prevalence of neurologic involvement (NI) in ANCA-associated vasculitis (AAV), especially central nervous system (CNS) involvement, is not well characterized. This project aimed to…Abstract Number: 0431 • ACR Convergence 2021
Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study
Background/Purpose: Hypertrophic pachymeningitis (HP) is an infrequent manifestation in autoimmune and non-autoimmune conditions. The differences in clinical characteristics and outcomes of ANCA-associated and non-immune-mediated HP…Abstract Number: 0651 • ACR Convergence 2021
Diagnostic Approach to Identifying Small Fiber Neuropathy in Patients with Sarcoidosis
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease that can affect the nervous system in about 5% of patients. Sarcoidosis associated small fiber neuropathy (SSFN) presents…